Complete Congenital Heart Block in a Newborn Associated with Maternal Systemic Lupus Erythematosus: A Case Report

Mahmoud A. Kiblawi,† Alina Naeem,† Elham A. Al Attrash,† Subhranshu Kar,† B. K. M. Goud†

Abstract

Background: Complete Congenital Heart Block (CCHB) is a rare disease of the newborn that carries significant morbidity and mortality. CCHB can be diagnosed early or late in life. In newborns, it is usually associated with maternal autoantibodies or a congenital cardiac structural abnormality. The most common presentation of CCHB is bradycardia that can be diagnosed by an electrocardiogram. Results: This is a case report of a male infant born to a mother with an autoimmune disease, Systemic Lupus Erythematosus (SLE), who was found to have third degree heart block at birth. Conclusion: Early diagnosis and prompt management of the case is important for a better prognosis and prevention of associated complications. Neonates with CCHB should be managed at a tertiary care center and the only definite treatment is insertion of a pacemaker. Moreover, prenatal diagnosis and specific obstetric counseling of pregnant women with SLE along with careful monitoring with serial ultrasonography and echocardiography are of paramount importance in prevention of the disease in subsequent offspring.

Keywords: Congenital Heart Block, Systemic Lupus Erythematosus, Bradycardia, SS-A Antibodies (Source: MeSH, NLM)

Introduction

Complete Congenital heart block (CCHB) is a rare clinical entity present in about 1 in 20,000 live births and has significant morbidity and mortality. It generally occurs due to the presence of maternal auto-antibodies, anti-Ro/SSA and anti-La/SSB, that are transferred across the placenta to the fetus and affect the fetal heart. More rarely, it may be associated with a congenital structural abnormality of the heart. The association between CCHB and maternal autoantibodies has been documented in different case reports.

The risk of Neonatal Lupus Erythematosus (NLE) or Congenital Heart Block (CHB) is 1% in infants with positive maternal autoantibodies to SSA/Ro. The risk is much higher if the mother already has had a child with NLE or has hypothyroidism due to thyroid autoantibodies that test positive for anti-Ro/SSA antibodies. The most common clinical manifestations of NLE are related to the cardiac, dermatologic and hepatobiliary systems. Some infants may also have hemolytic, central nervous system or splenic abnormalities. Infants with NLE have 15-30% risk of developing CHB.

In the early part of 19th century, congenital heart block was clinically recognized by slow pulse, syncopal attacks and ECG findings consistent with complete atrio-ventricular block leading to the death of the child early on in infancy. Considerable information has also been accumulated since then concerning the clinical profile and circulatory hemodynamics in such cases. Mortality is highest in the neonatal period and association with major cardiac malformations is a bad prognosis. We present a rare case of Complete Congenital Heart Block (CCHB) in a newborn associated with maternal Systemic Lupus Erythematosus (SLE). A written informed consent was obtained from the parents of the patient for the publication of the available data.

The Case

A 3-days-old full-term male infant, born out of a consanguineous marriage by normal vaginal delivery with a birth weight of 3,330 g, presented with bradycardia (heart rate of 40-65 beats/min) and respiratory distress for which he was admitted to special care baby unit (SCBU). His mother, Gravida 6 and Para 6, had a past medical history significant for Systemic Lupus Erythematosus (SLE) as positive anti-Ro/SS-A antibodies had been discovered 5 years ago. Her antibody titers have been persistently elevated since then. Furthermore, she has had persistent hypothyroidism over the past four years which currently being treated with levothyroxine. Also, two of her previously offspring were found positive when tested for Anti-nuclear Antibody (ANA) and anti-Ro/SSA antibodies.

The infant was stabilized in the SCBU and kept on two liters of oxygen through nasal cannula for respiratory distress. He was tolerating feeds. His heart rate ranged between 40-65 beats/min despite being given two doses of atropine (0.1 mg/dose). Laboratory examinations showed capillary blood sugar of 72 mg/dl, normal complete blood count and normal electrolyte levels (Na- 137 meq/L, K-3.6 meq/L). At presentation, the arterial blood gas analysis (pH-7.25, PCO₂-58 mmHg, PO₂-40 mmHg, HCO₃⁻-24 mmHg and base excess of -4) showed respiratory aci-
Case Report

dosis. Chest X-ray AP view showed cardiac enlargement (Figure 1). His electrocardiogram (ECG) showed features of complete heart block (Figure 2). Based on his condition, it was decided to do further evaluation and management (including the possibility of pacemaker insertion) to support the patient in the best possible way. Echocardiography was performed and it revealed no structural abnormality. A permanent pacemaker (St. Jude VVI PM at rate 90 beats/min) implantation was done on the 8th day of the infant’s life. Upon further follow up, the patient was stable and his general health status was good. The pacemaker was functioning well at a rate of 90 beats/min. He was thriving well with normal development.

Discussion
SLE is an autoimmune disease characterized by production of large amounts of circulating autoantibodies that can affect any organ of the body and leads to variable clinical manifestations. The ANA is the most sensitive laboratory test for the diagnosis of SLE. The presence of anti-double stranded DNA antibodies

---

**Figure 1. Anteroposterior (AP) Chest Radiograph of the Infant**

Note: Chest radiograph showed cardiac enlargement.

**Figure 2. ECG from Infant Demonstrating Complete Congenital Heart Block**

Note: ECG of the infant demonstrates no relation between P wave and QRS complex. The P wave has the normal rate and is regular, as it is arising from the sino-atrial node. The QRS complex illustrates the ventricular escape rhythm and hence is very slow.
These antibodies induce antigens of proteins, Ro52 and Ro660, with the former having close correlation with the development of CCHB. These antibodies induce myocarditis which leads to CCHB by destroying the cardiac conduction system at the atrioventricular node and bundle of His region. Atrioventricular (AV) block occurs due to impairment in the conduction system causing delay or block in transmission of atrial impulse to ventricles. Third-degree heart block, whether its congenital or acquired, is diagnosed when there is no association between P wave and QRS complexes. In less than 10% of cases, congenital AV block may be either 1st or 2nd degree block at birth, of which 50% progress to 3rd-degree block in postnatal life. Congenital heart block can be detected in utero between 18 and 28 weeks of gestation by echocardiography in the presence of fetal bradycardia. It may also be associated with other cardiac abnormalities such as endocardial fibroelastosis and dilated cardiomyopathy. As the fetal heart rate is an important indicator for the prognosis during the newborn period, the persistent bradycardia may eventually lead to increased size of both right and left ventricles. In children under three years of age, a heart rate less than 100 beats/min is considered as bradycardia. Our patient had a heart rate of 40-65 beats/min, whereas normal newborns have a heart rate of 120-160 beats/min. In spite of his low heart rate, his birth weight was within normal limits. The ECG showed the most severe type of heart block, third degree heart block, where there is no transmission of atrial impulse to the ventricle. CCHB is the most serious complication associated with maternal SLE and once established it is irreversible.

Occasionally, these cases are symptomatic in the neonatal period, as evident in our case, and they are considered high-risk patients requiring urgent intervention. The mortality is highest during the neonatal period. Glucocorticoid therapy is suggested for management of CCHB in utero and in the perinatal period (if associated with anti-Ro and anti-La antibodies), but the therapy itself carries high risk to both the mother and the fetus. Two third of all congenital heart block patients require pacemaker implantation and it is recommended in symptomatic bradycardia. Pacemaker therapy is recommended in infants with CCHB and heart rates less than 55 beats/min in the absence of structural heart disease or with rates less than 70 beats/min with concomitant congenital heart disease or signs of ventricular dysfunction. Beyond the first year of life, a heart rate less than 50 beats/min or abrupt pauses in ventricular rate merit consideration of pacing therapy. Evidence of cardiomyopathy with ventricular dysfunction, complex ventricular ectopy and wide complex escape rhythm are also indications for pacing. The primary goal of the pacemaker is to prevent sudden cardiac death and to provide symptomatic relief with improvement in quality of life and functional capacity, as was done in our case.

**Conclusion**

In conclusion, anticipation of CCHB in cases of maternal SLE is important. Early detection of CCHB by health care professionals and timely management is the key to the success of the infant’s survival. A thorough physical examination and an ECG can be diagnostic in patients presenting with bradycardia. For prevention, it is necessary to implement: 1) Health education and creating awareness among high risk populations, 2) Emphasize good antenatal care and proper screening, especially in underprivileged populations, because frequent assessment of fetal heart rate by echocardiography during pregnancy is beneficial for a patient with positive anti-Ro and anti-La antibodies, and 3) implementing proper obstetric counseling and support to the family.
Case Report

References

1. Michaelsson M, Engle MA. Congenital complete heart block: An internatio-
2012;2012:301274.
3. Admani S, Krakowski AC. Neonatal Lupus Erythematosus Presenting as
Atypical Targetoid-like Lesions Involving Genitals and Soles of Feet Following
4. Hardy JD, Solomon S., Banwell GS, Beach R, Wrigth V, Howard FM. Congeni-
tal complete heart block in the newborn associated with maternal systemic
lupus erythematosus and other connective tissue disorders. Arch Dis Child-
5. Winkler RB, Nora AH, Nora JI. Familial congenital complete heart block and
case-control study of congenital heart block: association with maternal anti-
7. Brucato A. Prevention of congenital heart block in children of SSA-positive
8. Mostasim K, Shirzad R, Escudier M, Poate T. Congenital heart block associat-
10. Boros CA, Spence D, Blaser S, Silverman ED. Hydrocephalus and ma-
crocephaly: new manifestations of neonatal lupus erythematosus. Arthritis
and fetal factors associated with mortality and morbidity in a multi-racial/
12. Morquio, L. Sur une maladie infantile et familiale characterisée par des
modifications permanentes du pouls, des attaques syncopales et epileptifor-
13. Yater WM. Congenital heart block; review of the Literature; Report of a
case with incomplete heterotaxy; the electrocardiogram in dextrocardia. Am
15. Lazzerini PL, Capechi PL, Guidetti F, Acampa M, Galeazzi M, Laghi Pasini
F. Connective tissue diseases and cardiac rhythm disorders: an overview.
16. Veille JC, Covitz W. Fetal cardiovascular hemodynamics in the presen-
tce of complete atrioventricular block. Am J Obstet Gynecol. 1994;170(5 Pt
17. Dipit TR, Azam MS, Sattar MK, Rahman SA. Detection of anti-nuclear anti-
body by immunofluorescence assay and enzyme immunoassay in childhood
systemic lupus erythematosus: experience from Bangladesh. Int J Rheum
18. Gordon PA. Congenital heart block: clinical features and therapeutic
genital heart: development of late-onset cardiomyopathy, a previously under
22. Chronister CS. Congenital complete atrioventricular block in a young man:
23. Ambrosi A, Wahren-Herlenius M. Congenital heart block: evidence for a
of children with fetal, neonatal or childhood diagnosis of isolated congenital
atrioventricular block. A single institution’s experience of 30 years. J Am Coll
une-associated congenital heart block: demographics, mortality, morbidity
and recurrence rates obtained from a national neonatal lupus registry. J Am
26. Guettrot-Imbert G, Cohen L, Ferront L, Villain E, Frances C, Theibau-
georges O, et al. A new presentation of neonatal lupus: 5 cases of isolated
mild endocardial fibroelastosis associated with maternal Anti-SSA/Ro and
27. Breur JM, Visser Gh, Kruise AA, Stoutenbeek P, Meijboom EJ. Treatment of
fetal heart block with maternal steroid therapy: case report and review of the
28. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA 3rd, Friedman RA, Mettes
LS, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac
Rhythm Abnormalities: a report of the American College of Cardiology/Ame-
lincan Heart Association Task Force on Practice Guidelines (Writing Committee
to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Car-
diac Pacemakers and Antiarrhythmia Devices): developed in collaboration
with the American Association for Thoracic Surgery and Society of Thoracic
29. Kaszala K, Huiziar JF, Ellenbogen KA. Contemporary pacemakers: what the

Acknowledgments

The authors would like to thank RAK Medical & Health Sciences University, Saqr Hospital, Dr. S. Gurumadhiva Rao Vice Chancellor of RAKHSU,
Dr. Kannan Murugesan Dean of RAK College of Medical Sciences, Dr. Saleh Ahmed Ali Hassan of pediatric department at Saqr Hospital, Dr.
Zito Lobo (English professor) RAKMHSU.

Conflict of Interest Statement & Funding

The Authors have no funding, financial relationships or conflicts of interest to disclose

Cite as:
Kiblawi M, Naeem A, Al Attrash E, Kar S, Goud B.K. Complete Congenital Heart Block in a Newborn associated with Maternal Systemic Lupus